Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

AEON Biopharma Inc

Contributing Author

Recent Articles by AEON Biopharma Inc

Aug-31
AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference AEON -5.82% GlobeNewswire
Aug-24
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer AEON GlobeNewswire
Aug-19
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX AEON -19.02% GlobeNewswire
Aug-12
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update AEON GlobeNewswire
Aug-03
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards AEON GlobeNewswire
Jul-14
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding AEON +10.84% GlobeNewswire
Jun-04
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society AEON GlobeNewswire
May-14
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update AEON AEON -9.91% GlobeNewswire
Apr-24
AEON Biopharma Sets Annual Shareholder Meeting AEON GlobeNewswire
Apr-03
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 AEON GlobeNewswire
Apr-03
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards AEON GlobeNewswire
Mar-30
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program AEON -14.70% GlobeNewswire
Mar-25
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program AEON GlobeNewswire
Mar-09
AEON Biopharma Appoints John Bencich as Chief Financial Officer AEON AEON +7.48% GlobeNewswire
Mar-05
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting AEON -5.50% GlobeNewswire
Jan-21
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions AEON +13.33% AEON -13.97% GlobeNewswire
Dec-19
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 AEON +6.93% GlobeNewswire
Dec-15
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong AEON +5.10% AEON +19.21% GlobeNewswire
Nov-20
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling AEON -12.79% GlobeNewswire
Nov-14
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth AEON GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)